Novel targeted therapies for eosinophilic disorders

Michael E. Wechsler*, Patricia C. Fulkerson, Bruce S. Bochner, Gail M. Gauvreau, Gerald J. Gleich, Tim Henkel, Roland Kolbeck, Sameer K. Mathur, Hector Ortega, Jatin Patel, Calman Prussin, Paolo Renzi, Marc E. Rothenberg, Florence Roufosse, Dagmar Simon, Hans Uwe Simon, Andrew Wardlaw, Peter F. Weller, Amy D. Klion

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

87 Scopus citations


Hypereosinophilic syndromes (HESs) are a diverse group of conditions characterized by clinical manifestations attributable to eosinophilia and eosinophilic infiltration of tissues. HESs are chronic disorders with significant morbidity and mortality. Although the availability of targeted chemotherapeutic agents, including imatinib, has improved quality of life and survival in some patients with HESs, additional agents with increased efficacy and decreased toxicity are sorely needed. The purpose of this review is to provide an overview of eosinophil biology with an emphasis on potential targets of pharmacotherapy and to provide a summary of potential eosinophil-targeting agents, including those in development, in clinical trials, or approved for other disorders.

Original languageEnglish (US)
Pages (from-to)563-571
Number of pages9
JournalJournal of Allergy and Clinical Immunology
Issue number3
StatePublished - Sep 2012


  • Churg-Strauss syndrome
  • Hypereosinophilic syndromes
  • IL-5
  • eosinophil-associated gastrointestinal disorders
  • eosinophilic esophagitis
  • mepolizumab
  • reslizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Novel targeted therapies for eosinophilic disorders'. Together they form a unique fingerprint.

Cite this